Latest News from Serpin Pharma
Latest News from Serpin Pharma
Manassas, VA – October 7, 2024.
Serpin Pharma, a Virginia-based biopharmaceutical company, is proud to announce that it has been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). This grant will support the clinical development of SP16-3M, a groundbreaking peptide drug designed to prevent chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer patients.
Manassas, VA – September 17, 2024.
Serpin Pharma, a leading clinical-stage pharmaceutical company, is thrilled to announce its partnership with Uniklinikum Erlangen in Germany for a groundbreaking clinical trial focused on preventing acute kidney injury (AKI). This Phase IIa trial will assess the efficacy and safety of SP163M, Serpin Pharma’s innovative therapeutic, in preventing AKI in at-risk patients with stage 2-3 chronic kidney disease (CKD) undergoing cardiac surgery.
Manassas, VA – July 8, 2024.
Serpin Pharma, a Virginia-based biopharmaceutical company, and HekaBio, headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN).
Manassas, VA – January 26, 2024. Sanofi’s recent acquisition of a recombinant alpha-1 antitrypsin (AAT) drug candidate for $2.2 billion highlights the critical need for innovative solutions in addressing the devastating consequences of inflammation. Serpin Pharma’s revolutionary SP16 platform drug is positioned to transform the treatment landscape with its unique approach.
Manassas, VA – January 24, 2024. Serpin Pharma, a pioneering clinical-stage pharmaceutical company headquartered in Virginia, has been awarded a competitive $900,000 grant by the Bi-national Industrial Research and Development (BIRD) Foundation. This grant is designated for the advancement of a randomized controlled Phase 2a clinical trial targeting acute myocardial infarction (AMI) patients. Collaborating with the esteemed Sheba Medical Center (Ramat Gan, Israel), a global leader in innovation cardiology care, Serpin Pharma aims to evaluate the efficacy of its novel anti-inflammatory and cell & tissue-healing drug, SP16.
Manassas, VA – January 12, 2024. Serpin Pharma, a leading biopharmaceutical company dedicated to development anti-inflammatory and immune-modulating drugs to treat human diseases caused by inflammation, proudly announces the appointment of Dr. Alexander Fleming as a new member of its esteemed Board of Directors. Dr. Fleming joins Dr. Cohava Gelber (Founder and CEO, Serpin Pharma), Dr. John Abeles, Dr. David Dove, and Mr. Guy Yachin.
Despite the success of combined antiretroviral therapy (cART) increasing the survival rate in human immunodeficiency virus (HIV) patients, low levels of viremia persist in the brain of patients leading to glia (microglia and astrocytes)- induced
Modulation of the inflammatory response is a promising therapeutic strategy in acute myocardial infarction. The novel approach is based upon the anti-inflammatory and cytoprotective
The intense inflammatory response triggered by myocardial infarction (MI) is part of the cardiac
repair process: infiltrating leukocytes, by releasing proteases and reactive oxygen species (ROS), clear the wound from dead cells and debris. Wound cleansing establishes, in turn, an environment which favors healing.
SP16 is an innovative peptide derived from the carboxyl-terminus of α1-Antitrypsin (AAT), corresponding to residues 364-380, and contains recognition sequences for the low-density lipoprotein receptor-related protein-1 (LRP1). LRP1 is an endocytic and cell-signaling receptor that regulates inflammation.
Serpin Pharma was selected for $1.25 M award by Catalyst Fund of VA to conduct COVID-19 clinical Investigation
Manassas, VA – On June 17, 2021, Serpin Pharma was selected to receive a $1.25 MM award from The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), for conducting a clinical investigation for the therapeutic role of SP16 drug in mitigating SARS COV2 (COVID-19) progression in hospitalized patients.
Manassas, VA – On June 17, 2020, Serpin Pharma was notified by the U.S. Food and Drug Administration (FDA) that it may proceed with its proposed clinical investigation for the use of SP16 to treat COVID-19 hospitalized patients. The Principal Investigator is Serpin Pharma’s collaborator, Dr. Michael Yun Shim, John L. Guerrant Assoc. Professor of Medicine and Medical Imaging, Div. of Pulmonary & Critical Care of the University of Virginia.
Serpin Pharma, a privately held biotech company with research facilities in Innovation Park, Manassas, is the second company to graduate from the Prince William Science Accelerator and move within a mile — quadrupling the company’s footprint while staying in the bioscience hub.
Low-density lipoprotein receptor–related protein-1 (LRP1) is a ubiquitous membrane receptor functioning as a scavenger and regulatory receptor, inducing anti-inflammatory and prosurvival signals.
Acute myocardial infarction (AMI) leads to myocardial cell death and ensuing sterile inflammatory response, which represents an attempt to clear cellular debris and promote cardiac repair.
Endogenous serine protease inhibitors are associated with anti-inflammatory and pro-survival signaling mediated via Low-density lipoprotein receptor-related protein 1 (LRP1) signaling. SP16 is a short polypeptide that mimics the LRP1 binding portion of alpha-1 antitrypsin.
Copyright © Serpin Pharma,
LLC 2022 - All Rights Reserved
